Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera

NCT06193408 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholera

Interventions

DRUG: VR-AD-1005
DRUG: Placebo

Sponsor

Hunazine Biotech S.L.